KRAS and non-small cell lung carcinoma: In addition, a phase 2 trial results of sotorasib for lung cancers with KRAS G12C mutation showed that the mPFS was 6.8 months (95% CI, 5.1 to 8.2) and the mOS was 12.5 months (95% CI, 10.0 to could not be evaluated) (34).Due to a higher level of PD-L1 expression, T cell infiltration, and tumor immunogenicity, the KRAS/TP53 co-mutation in NSCLC exhibited sensitivity to anti-PD-1/PD-L1 immunotherapy (17).